3 results about "Immunologic disease" patented technology

To provide new and improved methods of treating cancer, immune disorders, and other diseases utilizing borylated amino acids and neutron capture therapy (NCT).SOLUTION: Disclosed herein are borylated amino acid ("BAA") compositions and methods of making BAAs. Accordingly, BAAs can be administered to patients as neutron capture agents and can provide methods of treating cancer, immune disorders, and other diseases by utilizing neutron capture therapy modalities. The invention described herein relates to the field of boron neutron capture therapy (BNCT). In particular, the present invention relates to borylated amino acid ("BAA") or ("BAAs") compositions that can be used as a vehicle for neutron capture therapy in humans. The invention further relates to the treatment of cancer and other immune disorders and diseases.SELECTED DRAWING: None

The invention provides an immune disease risk assessment method. The method comprises the following steps: acquiring TCR sequence data of each sample in a training set and a test set; the TCR sequence data comprises data obtained by embedding an amino acid sequence of each high-expression TCR [beta] CDR3 after quality control into a high-dimensional vector through a pre-trained protein language model; obtaining the risk score of the immune disease of the corresponding object through a convolutional neural network by using the TCR sequence data of the training set and the test set; through a multi-fold cross validation training model, calculating indexes of the trained model of each fold, and selecting an optimal model as a risk prediction model of the immune disease based on the F1 value; and obtaining TCR sequence data of the detected object, and inputting the TCR sequence data into the risk prediction model for risk assessment to obtain the risk score of the immune disease of the detected object. The method focuses on a CDR3 region of a TCR beta chain, and comprehensively reflects the core effect of T cells in immune response and close association of the T cells with immune diseases.

The present invention relates to the new use of a drug for intervening with a HIF2α target. It has been found that HIF2α has an influence on Th2 cell differentiation, thereby playing a significant role in type II immune diseases, tumors, diseases caused by dysregulated Th2 / ILC2 differentiation, and aging. Furthermore, it has been validated that intervention with HIF2α can be used for the prevention and treatment of type II immune diseases and diseases caused by dysregulated Th2 / ILC2 differentiation, and for anti-tumor, anti-aging and anti-aging-related disease uses. The present invention provides a new potential target for the clinical treatment of type II immune diseases, tumors and diseases caused by dysregulated Th2 / ILC2 differentiation, and for anti-aging and anti-aging-related disease uses, and has good application prospects.